Clinical trials: Hypersensitivity, Immediate
Asthma
An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Asthma
This study is designed to compare the effectiveness and safety of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate ((FF), GW685698)/25mcg Vilanterol ((VI), GW642444) or 200mcg Fluticasone Furoate…
- Trial name
- NCT01706198
- Testing
- fluticasone furoate + vilanterol, inhaled corticosteroid with or without a long acting beta2-agonist
- Where
- 180 sites in United Kingdom
- Volunteers
- 4,233 people
- Sponsor
- GlaxoSmithKline
Asthma
A Phase IIA FF/VI Study to Measure FeNO in Asthmatic Patients.
For asthmatic subjects, a combination of inhaled corticosteroid (FF) and long-acting beta2 receptor agonist (VI) is recommended for use (once daily) and fraction of exhaled nitric oxide (FeNO) is a non-invasive airway…
- Trial name
- NCT02712047
- Testing
- Fluticasone furoate (FF) (100 mcg), Vilanterol (VI) (25 mcg)
- Where
- New Zealand
- Volunteers
- 28 people
- Sponsor
- GlaxoSmithKline
Urticaria
A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants Previously Enrolled in a Fenebrutinib Chronic Spontaneous Urticaria (CSU) Study
This is a Phase II, multicenter, open-label extension (OLE) study to evaluate the long-term safety and efficacy of fenebrutinib in participants with Chronic Spontaneous Urticaria (CSU) who have completed the treatment period in a…
- Trial name
- NCT03693625
- Testing
- GDC-0853
- Where
- 10 sites in United States
- Volunteers
- 31 people
- Sponsor
- Genentech, Inc.
Asthma
A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 and FF in Japanese Subjects With Asthma
The primary purpose of the study is to assess the safety and tolerability of 52-week teatment with fluticasone furoate/GW642444 inhalation powder once-daily and FF inhalation powder once-daily in Japanese adult subjects with…
- Trial name
- NCT01244984
- Testing
- Fluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate Inhalation Powder
- Where
- 30 sites in Japan
- Volunteers
- 243 people
- Sponsor
- GlaxoSmithKline
Atopic Dermatitis
Measuring Adherence to Topical Therapy in Children With Atopic Dermatitis and the Impact of a Return Visit
The purpose of this research study is to better understand how the study drug works when people use it to treat atopic dermatitis.
- Trial name
- NCT00654355
- Testing
- tacrolimus ointment
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Wake Forest University
Food Allergy, Food Allergy Peanut
Preventing Anaphylaxis With Acalabrutinib
Food allergy is a potentially life-threatening condition, and its prevalence continues to increase despite public health efforts. There are currently no known therapies that can reliably prevent food-induced anaphylaxis.
- Trial name
- NCT05038904
- Testing
- Acalabrutinib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Johns Hopkins University
Hereditary Angioedema
Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II
KVD900-303 is an open-label, multicenter clinical trial in patients aged 2 to 11 years old with HAE Type I or II.
- Trial name
- KONFIDENT-KID (NCT06467084)
- Testing
- KVD900 150 mg, KVD900 300 mg, KVD900 600 mg
- Where
- 24 sites in United States, Canada and 5 more
- Volunteers
- 36 people
- Sponsor
- KalVista Pharmaceuticals, Ltd.
Coronary Artery Disease, Asthma
Comparison of Dobutamine and Regadenoson Stress Cardiac Magnetic Resonance (MR)
The goal of this research is to determine the utility of Regadenoson (Lexiscan)for use as an imaging agent with cardiac MR. If found useful, it will help us establish a protocol for regadenoson stress MR perfusion (Regadenoson…
- Conditions
- Coronary Artery Disease, Asthma, Chronic Obstructive Pulmonary Disease (COPD), Angina
- Trial name
- NCT00763035
- Testing
- Regadenoson, Dobutamine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Wake Forest University Health Sciences
Asthma, Bronchial Hyperresponsiveness
The Effect of HFA - Beclomethasone Dipropionate Qvar on Bronchial Hyperreactivity in Preschool Children
Respiratory diseases including Asthma are high prevalent among preschool children. Specific treatment, nowadays, include steroid inhalers and anti leukotrienes.
- Trial name
- NCT01006655
- Testing
- Beclomethasone dipropionate HFA
- Where
- Israel
- Volunteers
- 21 people
- Sponsor
- Rambam Health Care Campus
Atopic Dermatitis
A Study to Assess the Safety and Efficacy of ZPL389 With TCS/TCI in Atopic Dermatitis Patients
This extension study (CZPL389A2203E1) was designed as a 2-year (100 weeks) extension to the core study (CZPL389A2203/ NCT03517566) which is disclosed separately.
- Trial name
- ZESTExt (NCT03948334)
- Testing
- ZPL389 30mg, ZPL389 50mg, TCS and/or TCI
- Where
- 48 sites in United States, Belgium and 11 more
- Volunteers
- 123 people
- Sponsor
- Novartis Pharmaceuticals
Asthma, Communication
A Patient Advocate to Improve Real-world Asthma Management for Inner City Adults
Few interventions to improve asthma management have targeted low-income minority asthmatic adults and even fewer have focused on the real-world practice where care is provided for these patients.
- Trial name
- HAP2 (NCT01972308)
- Testing
- Patient Advocate, Usual Care
- Where
- United States
- Volunteers
- 312 people
- Sponsor
- University of Pennsylvania
Peanut Allergy
Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy
The objectives of this dose-finding study for the treatment of peanut allergy are: To determine the efficacy of 3 doses of Viaskin Peanut (50 mcg ,100 mcg and 250 mcg peanut protein per patch) to significantly desensitize…
- Trial name
- VIPES (NCT01675882)
- Testing
- Viaskin Peanut 50 mcg, Viaskin Peanut 100 mcg, Viaskin Peanut 250 mcg
- Where
- 24 sites in United States, Canada and 3 more
- Volunteers
- 221 people
- Sponsor
- DBV Technologies
Atopic Dermatitis
A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic…
- Trial name
- Level Up (NCT05601882)
- Testing
- Dupilumab, Upadacitinib
- Where
- 257 sites in United States, Australia and 27 more
- Volunteers
- 920 people
- Sponsor
- AbbVie
Asthma
Extended Safety Study of Montelukast in Infants and Young Children With Chronic Asthma (0476-232)
Patients were treated with either montelukast 4 mg oral granules or usual care. Patients who completed Protocol MK0476-176-01 (NCT00943683) had the option to enroll in this study.
- Trial name
- NCT00943397
- Testing
- montelukast sodium, Comparator: Usual Care
- Volunteers
- 190 people
- Sponsor
- Organon and Co
Asthma
Comparing Maintenance of Device Mastery With Turbohaler© vs. Spiromax© in Healthcare Professionals naïve to Both Devices
This study is conducted to assess the ease of device mastery of a placebo SYMBICORT TURBOHALER vs a placebo Budesonide/Formoterol SPIROMAX device among healthcare professionals in-training (HCP).
- Trial name
- HCP-ELIOT (NCT02570425)
- Testing
- Training on BF Spiromax followed by SYMBICORT Turbohaler, Training on SYMBICORT Turbohaler followed by BF Spiromax
- Volunteers
- 516 people, healthy volunteers welcome
- Sponsor
- Research in Real-Life Ltd
Atopic Dermatitis
Apremilast 30 mg Twice Daily (BID) Combined With Dupilumab
Open label phase 2 investigational study of efficacy and safety of apremilast 30 mg twice a day (BID) in chronic atopic dermatitis when added to the FDA approved treatment dupilumab for atopic dermatitis that is not providing…
- Trial name
- NCT04306965
- Testing
- Apremilast
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Tufts Medical Center
Rhinitis, Allergic, Perennial
Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR)
The primary objective of this study is to compare the efficacy and safety of GW685698X 100mcg once daily (QD) aqueous nasal spray with vehicle placebo nasal spray in adult and adolescent subjects (12 years of age and older) with…
- Trial name
- NCT00289198
- Testing
- FF
- Where
- 42 sites in United States, Australia and 7 more
- Volunteers
- 301 people
- Sponsor
- GlaxoSmithKline
Atopic Dermatitis
A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Participants With Atopic Dermatitis (AD)
The purpose of this study was to evaluate the pharmacokinetics and safety of nemolizumab in adolescent participants with AD.
- Trial name
- NCT03921411
- Testing
- Nemolizumab
- Where
- 10 sites in United States
- Volunteers
- 20 people
- Sponsor
- Galderma R&D
Asthma
A Non-inferiority Study to Evaluate the Efficacy, Safety, and Tolerability of Combination Dry Powder of Fluticasone Propionate and Salmeterol (FSC) 250/50 Microgram (mcg) Twice Daily (BID) in Adults and Adolescents With Asthma
This is a multi-centre, randomised, double-blind, double-dummy, two way cross-over, 12 week non inferiority study to evaluate the efficacy, safety, and tolerability of FSC 250/50 mcg capsule-based inhaler and FSC 250/50 mcg…
- Trial name
- NCT01978119
- Testing
- FSC
- Where
- 13 sites in Russia, Ukraine
- Volunteers
- 124 people
- Sponsor
- GlaxoSmithKline
Asthma
Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma
This is a study to establish the equivalence of OT329 Solis and Advair Diskus when administered by inhalation in patients with asthma.
- Trial name
- NCT02260492
- Testing
- OT329 (combination of fluticasone propionate and salmeterol xinafoate), Advair Diskus (combination of fluticasone propionate and salmeterol xinafoate)
- Where
- 47 sites in United States
- Volunteers
- 879 people
- Sponsor
- Oriel Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.